
Our Platform
Two different lung-specific bacterial chassis (MycoChassis and LactoChassis), designed to treat acute and chronic respiratory diseases, respectively. These chassis are able to expose antigens or deliver therapeutic agents in the lung in a controlled, local and continuous manner.

IMMUNE SYSTEM MODULATION

Lung Cancer
Immune stimulatory interleukins, nanobodies against immune check point inhibitors

Asthma
Modified interleukins
nanobodies

Pulmonary alveolar proteinosis
GM-CSF mutants
ANTIMICROBIAL AND BIOFILM DISPERSION
ACUTE

Cystic Fibrosis
Infectious diseases
Antibacterial and
biofilm-dispersing agents

VAP
Infectious diseases
Antibacterial and
biofilm-dispersing agents
PROTEIN SUPPLEMENTATION
FOR GENETIC DISEASES

Chronic obstructive
Pulmonary disease
A1AT

Interstitial lung disease
Surfactant proteins
Publications by scientific team












